SEC Tracker
Get the app

111 YI

111 FY 2024: revenue $14.4B, down 4%; diluted EPS −$0.38

Form
20-F/A
Filed
Period
Importance
Routine
Document
20-F/A

Key figures from this report

These are the numbers 111 reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$14.4B−4% from $14.9B in FY 202320-F/A income statement, on EDGAR
  2. Diluted EPS−$0.38Against −$2.33 in FY 202320-F/A income statement, on EDGAR
  3. Cash and cash equivalents$462.3M−23% from $603.5M in FY 202320-F/A balance sheet, on EDGAR
  4. Cash from operations$263.0MAgainst −$447.2M in FY 202320-F/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when 111 files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 5912 and related industry codes: the same peer list as the financial tables.

  1. AiXin Life International AIXN public float $884K, Jun 30, 2025
  2. TREES Corp (Colorado) CANN
  3. CVS Health CVS public float $86.4B, Jun 30, 2025
  4. Flowerkist Skin Care & Cosmetics FKST
  5. Guardian Pharmacy Services GRDN public float $412M, Jun 30, 2025